Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in Non-Allergic Rhinitis with Eosinophilia Syndrome (ESSNARES)
NCT07240376Not yet recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial in Non-allergic rhinitis with eosinophilia syndrome (NARES) comparing CM310 group with Placebo group (2 arms). Primary endpoint: Reflective Total Nasal Symptom Score at 12 weeks. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
Non-allergic rhinitis with eosinophilia syndrome (NARES)
Beyond the preview
Go deeper on NCT07240376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240376.